Merck KGaA Profit Beats Estimates on Cost-Cutting

May 14 (Bloomberg) -- Merck KGaA, the German maker of cancer drug Erbitux, said first-quarter profit rose on higher-than-expected savings from a reorganization program, and forecast it will achieve 2014 targets a year ahead of schedule. Mark Barton reports on Bloomberg Television's "Countdown." (Source: Bloomberg)
Fed Will Hike Rates in December: Redeker
29:12 - Morgan Stanley Head of Global FX Strategy Hans Redeker discusses the Federal Reserve statement due out later today, when the Fed will hike interest rates and the impact of the rate hike on global currencies. He speaks to Bloomberg’s Anna Edwards on “Countdown.” (Source: Bloomberg)
  • Scale Mont Blanc Without Breaking a Sweat
  • What You Need to Know: Fed, Twitter, Greece
  • Canadians Take a Punt on Irish Gold